MedWatch

Zealand Pharma sends obesity candidate to clinic

Zealand Pharma has started a phase I study of the drug candidate ZP8396, which the company hopes will become an effective treatment for obesity. The trial is expected to be finished in September 2022.

Emmanuel Dulac - CEO at Zealand Pharma | Photo: Stine Bidstrup ERH

Danish pharmaceutical company Zealand Pharma wants a slice of the lucrative market for obesity treatments.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs